Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Oral ridaforolimus plus trastuzumab for patients with HER2+ trastuzumab-refractory metastatic breast cancer

M. Seiler, I. Ray-Coquard, B. Melichar, DA. Yardley, RX. Wang, PF. Dodion, MA. Lee,

. 2015 ; 15 (1) : 60-5. [pub] 20140817

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky, fáze II, časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc16000614

BACKGROUND: Although trastuzumab-containing therapies prolong survival in patients with metastatic breast cancer (MBC), most tumors develop trastuzumab resistance, potentially mediated by aberrant phosphatidylinositide 3-kinase (PI3K)/AKT signaling. Ridaforolimus (a mammalian target of rapamycin [mTOR] inhibitor) may overcome trastuzumab resistance by inhibiting PI3K signaling. METHODS: A single-arm, phase IIb trial was conducted to evaluate the efficacy and safety of ridaforolimus-trastuzumab in human epidermal growth factor receptor 2-positive (HER2(+)) trastuzumab-refractory MBC (NCT00736970). Ridaforolimus was administered orally (40 mg daily) for 5 d/wk plus weekly trastuzumab. The primary end point was objective response (OR). RESULTS: Thirty-four patients were enrolled (91% had received 1 or 2 previous trastuzumab-based therapies, whereas 9% had received 3 previous therapies). The most common reasons for discontinuation were disease progression (62%) and adverse events (AEs; 24%). Three patients died; 1 because of bowel perforation, which was possibly ridaforolimus related. Partial response was observed in 5 patients (15%). Median duration of response was 19.1 weeks (range, 15.9-80.1 weeks). Fourteen patients (41%) achieved stable disease (SD); 7 patients (21%) maintained SD for ≥ 24 weeks. The clinical benefit response (CBR) rate was 34.3%. Median progression-free survival (PFS) and overall survival (OS) were 5.4 months (range, 0-20.3 months; 95% confidence interval [CI], 2.0-7.4) and 17.7 months (range, 0-25.9 months; 95% CI, 8.8-20.8), respectively. PFS rate at 6 months was 37%. The most common treatment-related AEs were stomatitis (59%), diarrhea (27%), and rash (27%). CONCLUSION: Ridaforolimus-trastuzumab was well tolerated and demonstrated antitumor activity in trastuzumab-resistant HER2(+) MBC.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16000614
003      
CZ-PrNML
005      
20200121094209.0
007      
ta
008      
160108s2015 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.clbc.2014.07.008 $2 doi
035    __
$a (PubMed)25239224
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Seiler, Milton $u Hematology and Oncology Specialists, LLC, New Orleans, LA. Electronic address: milton.seiler@touro.com.
245    10
$a Oral ridaforolimus plus trastuzumab for patients with HER2+ trastuzumab-refractory metastatic breast cancer / $c M. Seiler, I. Ray-Coquard, B. Melichar, DA. Yardley, RX. Wang, PF. Dodion, MA. Lee,
520    9_
$a BACKGROUND: Although trastuzumab-containing therapies prolong survival in patients with metastatic breast cancer (MBC), most tumors develop trastuzumab resistance, potentially mediated by aberrant phosphatidylinositide 3-kinase (PI3K)/AKT signaling. Ridaforolimus (a mammalian target of rapamycin [mTOR] inhibitor) may overcome trastuzumab resistance by inhibiting PI3K signaling. METHODS: A single-arm, phase IIb trial was conducted to evaluate the efficacy and safety of ridaforolimus-trastuzumab in human epidermal growth factor receptor 2-positive (HER2(+)) trastuzumab-refractory MBC (NCT00736970). Ridaforolimus was administered orally (40 mg daily) for 5 d/wk plus weekly trastuzumab. The primary end point was objective response (OR). RESULTS: Thirty-four patients were enrolled (91% had received 1 or 2 previous trastuzumab-based therapies, whereas 9% had received 3 previous therapies). The most common reasons for discontinuation were disease progression (62%) and adverse events (AEs; 24%). Three patients died; 1 because of bowel perforation, which was possibly ridaforolimus related. Partial response was observed in 5 patients (15%). Median duration of response was 19.1 weeks (range, 15.9-80.1 weeks). Fourteen patients (41%) achieved stable disease (SD); 7 patients (21%) maintained SD for ≥ 24 weeks. The clinical benefit response (CBR) rate was 34.3%. Median progression-free survival (PFS) and overall survival (OS) were 5.4 months (range, 0-20.3 months; 95% confidence interval [CI], 2.0-7.4) and 17.7 months (range, 0-25.9 months; 95% CI, 8.8-20.8), respectively. PFS rate at 6 months was 37%. The most common treatment-related AEs were stomatitis (59%), diarrhea (27%), and rash (27%). CONCLUSION: Ridaforolimus-trastuzumab was well tolerated and demonstrated antitumor activity in trastuzumab-resistant HER2(+) MBC.
650    _2
$a aplikace orální $7 D000284
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a humanizované monoklonální protilátky $x aplikace a dávkování $x škodlivé účinky $7 D061067
650    _2
$a protokoly protinádorové kombinované chemoterapie $x aplikace a dávkování $x škodlivé účinky $7 D000971
650    _2
$a nádory prsu $x farmakoterapie $x mortalita $x patologie $7 D001943
650    _2
$a duktální karcinom prsu $x farmakoterapie $x mortalita $x patologie $7 D018270
650    _2
$a chemorezistence $x účinky léků $7 D019008
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a lidé středního věku $7 D008875
650    _2
$a metastázy nádorů $7 D009362
650    _2
$a receptor erbB-2 $x metabolismus $7 D018719
650    _2
$a sirolimus $x aplikace a dávkování $x škodlivé účinky $x analogy a deriváty $7 D020123
650    _2
$a analýza přežití $7 D016019
650    _2
$a trastuzumab $7 D000068878
655    _2
$a klinické zkoušky, fáze II $7 D017427
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Ray-Coquard, Isabelle $u Département d'oncologie médicale adulte, Lyon, France.
700    1_
$a Melichar, Bohuslav $u Department of Oncology, Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic.
700    1_
$a Yardley, Denise A $u Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN.
700    1_
$a Wang, Rui X $u Biostatistics and Research Decision Sciences, Asia Pacific MSD R&D (China) Co. Ltd., Beijing, China.
700    1_
$a Dodion, Pierre F $u ARIAD Pharmaceuticals, Inc., Cambridge, MA.
700    1_
$a Lee, Mark A $u Merck & Co., Inc., Whitehouse Station, NJ.
773    0_
$w MED00188740 $t Clinical breast cancer $x 1938-0666 $g Roč. 15, č. 1 (2015), s. 60-5
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25239224 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160108 $b ABA008
991    __
$a 20200121094545 $b ABA008
999    __
$a ok $b bmc $g 1102895 $s 924820
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 15 $c 1 $d 60-5 $e 20140817 $i 1938-0666 $m Clinical breast cancer $n Clin Breast Cancer $x MED00188740
LZP    __
$a Pubmed-20160108
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace